Regentis Biomaterials Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its GelrinC® platform, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure. The company aims to address an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.

GelrinC® offers an alternative to traditional microfracture and complex cell-based therapies. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The product has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled.

According to the company, several upcoming catalysts could drive further momentum, including potential European commercialization, completion of the pivotal study, and eventual FDA submission. For more details, a full corporate profile is available at https://ibn.fm/bpPp6.

Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC® is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.

The significance of this development lies in the potential to fill a gap in the U.S. market, where approximately 470,000 cases of cartilage knee repair occur annually, and no off-the-shelf treatment is currently approved. If successful, GelrinC® could provide a simpler, more accessible option for patients and physicians.

Investors can stay updated with the latest news and updates relating to RGNT at the company’s newsroom: https://ibn.fm/RGNT.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Regentis Biomaterials Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones.

The post Regentis Biomaterials Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones appeared first on citybuzz.